Blood Tests After COVID-19: What Changes in Your Labs

What COVID-19 Does to Your Blood

COVID-19 causes a complex immunological response that affects blood composition in multiple ways simultaneously. The SARS-CoV-2 virus infects cells lining blood vessels (endothelial cells), triggers excessive immune activation, causes a hypercoagulable state (increased clotting tendency), and in severe cases leads to a cytokine storm — an uncontrolled inflammatory cascade that damages organs far beyond the lungs.

Even in mild-to-moderate COVID, inflammation markers rise significantly. Understanding which changes are expected and transient versus which are persistent warning signs is important for anyone recovering from infection.

Key Blood Changes During Acute COVID-19

Biomarker	What Happens in Acute COVID	Clinical Significance
CRP	Rises dramatically (often 50–200 mg/L in moderate-severe)	Correlates with severity; very high CRP predicts ICU risk
D-dimer	Elevated — microclot formation throughout vasculature	High D-dimer associated with thrombosis risk and mortality
Ferritin	Very high — acute phase reactant in severe COVID	Extremely elevated ferritin (>1500) indicates cytokine storm risk
Lymphocytes	Low (lymphopenia) in moderate-severe cases	Marker of immune system fighting infection; low count = worse prognosis
Neutrophil-to-lymphocyte ratio	High — high neutrophils, low lymphocytes	NLR >6 is a strong predictor of severe disease
LDH (lactate dehydrogenase)	Elevated — cell damage marker	High LDH signals tissue destruction, lung damage
Troponin	May be elevated even without pre-existing heart disease	COVID-related myocarditis or cardiac stress
ALT/AST	Mildly elevated in many cases	Direct viral liver infection or inflammation

D-Dimer and Clotting Risk

One of COVID's most dangerous features is its tendency to cause microclots — tiny fibrin clots in small blood vessels throughout the body. D-dimer, a fibrin degradation product, rises as these clots form and break down. Levels above 1.0 µg/mL (or 1000 ng/mL) during acute infection significantly increase the risk of pulmonary embolism, deep vein thrombosis, and stroke.

In hospitalised patients, D-dimer is monitored repeatedly and used to guide anticoagulation decisions. In outpatients with mild COVID, D-dimer is not routinely checked — but those with persistent shortness of breath, leg swelling, or chest pain after COVID should have it checked urgently to rule out pulmonary embolism.

Long COVID and Blood Markers

Long COVID — defined as symptoms persisting more than 12 weeks after initial infection — affects an estimated 10–15% of those who have had COVID-19. Standard blood tests often appear normal in long COVID patients, which contributes to a frustrating lack of diagnosis. However, specialised testing has revealed several persistent abnormalities:

It is important to note that many of these findings are from research studies rather than standard clinical tests — they may not be routinely available or interpretable outside a research context. The field is evolving rapidly.

Blood Tests to Run After COVID-19

When	Tests to Consider	Why
4–8 weeks post-recovery	CBC, CRP, D-dimer, liver function, glucose	Confirm resolution of acute inflammation and organ function
If persistent fatigue	Ferritin, thyroid panel, vitamin D, B12, cortisol	Rule out COVID-unmasked or worsened deficiencies
If brain fog or cognitive symptoms	Thyroid, B12, folate, ferritin, fasting glucose	Treatable metabolic causes of cognitive slowing
If chest symptoms persist	D-dimer, troponin, BNP/NT-proBNP, ECG	Rule out pulmonary embolism, myocarditis, pericarditis
3–6 months post-COVID	HbA1c, fasting glucose, lipid panel	COVID increases risk of new-onset diabetes and dyslipidaemia

COVID and New-Onset Diabetes Risk

Multiple large studies have found that COVID-19 infection significantly increases the risk of developing type 2 diabetes in the months following infection — by as much as 40–80% compared to matched controls who did not have COVID. The mechanism appears to involve direct infection of pancreatic beta cells, as well as insulin resistance driven by the inflammatory response.

Anyone who had moderate or severe COVID should have a fasting glucose and HbA1c checked at their 3–6 month follow-up, even if they had no prior diabetes risk. Early detection of impaired fasting glucose allows intervention before full-blown diabetes develops.

When Blood Tests Look Normal but Symptoms Persist

Many long COVID patients have entirely normal standard blood panels — normal CBC, normal CRP, normal metabolic panel, normal thyroid. This does not mean nothing is wrong; it means the problem is not currently detectable with standard tests. Research is ongoing into specialist testing including microclot assays, mitochondrial function, and cytokine panels, but these are not yet in routine clinical use.

The most useful role of blood testing in long COVID is excluding treatable mimics — thyroid disease, anaemia, vitamin deficiencies, new-onset diabetes — that may have been triggered or unmasked by COVID and are contributing to symptoms independently.